Webinar  |  






11:00 am



Industry Perspectives:

Best Practices on how to Navigate the Evolving eConsent and DCT Landscape In 2021

Register to join session

Watch On-Demand

With eConsent continuing to make in-roads with trials across the globe, many sponsors have found themselves challenged by evolving regulations, data standards, participant preferences and new ways of working, making it difficult to plan for success. 

In this webinar, we’ll sit down with industry experts Alison Holland and Pamela Tenaerts to dive into the current state of eConsent and Televisit solutions around the world as well as lessons learned from our latest study completions and best practices for the future. 

If you’re curious to learn more about how you can navigate the evolving eConsent landscape and set up your studies for success then don’t wait! 

Alison Holland
Executive GM, Digital and Decentralized Solutions

Alison (Ali) Holland is Executive GM, Digital and Decentralized Solutions at Medable and is chartered to design and expand the end-to-end capabilities needed to partially or fully virtualize clinical studies, building on the commitment to reduce clinical trial times by 50%. Ali has over 20 years of experience in a variety of leadership roles, including Feasibility Head and Six Sigma Black Belt at Covance, and Business Head and global General Manager at Roche/Genentech in one of their therapeutic area business groups. Having been engaged in over 300 studies across Biotechs, Pharma and all geographies, Ali brings unparalleled clinical insight and technical excellence on the matter of operational needs for sites and patients.

Pamela Tenaerts
Chief Scientific Officer

As Chief Scientific Officer, Dr. Pamela Tenaerts oversees Medable’s clinical research department to help identify, develop and implement responsible decentralized trial strategies for sponsors, sites and patients. Dr. Tenaerts brings more than 30 years of experience in clinical trials, as a researcher, academic and physician, most recently serving as Executive Director of the Clinical Trials Transformation Initiative (CTTI) at Duke University. She is a Board Member of the Society of Clinical Trials and the Scientific Leadership Council of the Digital Medicine Society and participates in the Good Clinical Trial Collaborative and the National Academies of Science and Medicine: Forum on Drug Discovery, Development and Translation. She received her MD from KU Leuven and her MBA from the University of South Florida.